IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:02 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:02 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
Are Options Traders Betting on a Big Move in IDEXX Laboratories (IDXX) Stock?
by Nandini Tamret
Investors need to pay close attention to IDEXX Laboratories (IDXX) stock based on the movements in the options market lately.
Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
Why Is Idexx (IDXX) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Do Options Traders Know Something About IDEXX (IDXX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to IDEXX (IDXX) stock based on the movements in the options market lately.
IDEXX (IDXX) Q2 Earnings Miss Estimates, 2024 View Down
by Zacks Equity Research
IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.
Idexx (IDXX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Idexx Laboratories (IDXX) Lags Q2 Earnings Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of -14.98% and 0.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Baxter International, Henry Schein and IDEXX Laboratories
by Zacks Equity Research
Baxter International, Henry Schein and IDEXX Laboratories are included in this Analyst Blog.
What's in Store for These 3 MedTech Stocks in Q2 Earnings?
by Urmimala Biswas
MedTech companies' quarterly results are likely to be strong on a sequential basis. Let's see how BAX, HSIC and IDXX are placed ahead of their earnings releases.
Unlocking Q2 Potential of Idexx (IDXX): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Idexx (IDXX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Will KORU Medical Systems Inc. (KRMD) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
KORU Medical Systems Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strong CAG Sales to Aid IDEXX Laboratories' (IDXX) Q2 Earnings
by Zacks Equity Research
IDEXX Laboratories' (IDXX) second-quarter 2024 results are likely to reflect the benefits of strong execution against the growth strategy.
TMO or IDXX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TMO vs. IDXX: Which Stock Is the Better Value Option?
IDEXX (IDXX) Business Faces Macroeconomic Woes, FX Headwinds
by Zacks Equity Research
IDEXX's (IDXX) supply chain operations bear the brunt of geopolitical instability, including the current war in Ukraine.
Why Is Penumbra (PEN) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IDEXX (IDXX) Expands Test Menu for the Catalyst Platform
by Zacks Equity Research
IDEXX's (IDXX) new Catalyst Pancreatic Lipase Test is likely to support veterinarians globally in diagnosing pancreatitis.
Why Is Idexx (IDXX) Up 5% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IDEXX (IDXX) Witnesses Rising Expenses, Currency Issues
by Zacks Equity Research
IDEXX (IDXX) is being hurt by geopolitical instability, including the current war in Ukraine, which has affected supply chain operations globally.
IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed
by Zacks Equity Research
IDEXX (IDXX) delivers better-than-expected earnings in the first quarter of 2024.
Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Idexx (IDXX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Idexx Laboratories (IDXX) Tops Q1 Earnings Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 4.85% and 0.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Bruker's (BRKR) Balanced Segmental Growth, Innovation Aid
by Zacks Equity Research
Bruker (BRKR) revenues continue to be driven by the strength of end markets, including academic, government and industrial.
Philips (PHG) Receives FDA Warning Letter Regarding CT Systems
by Zacks Equity Research
Philips (PHG) receives a warning letter from the FDA in respect of a manufacturing plant in China regarding faults in the manufacturing of CT systems.
Seeking Clues to Idexx (IDXX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Idexx (IDXX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.